Krebs Biochemicals & Industries Ltd Financials
Company Logo

Krebs Biochemicals & Industries Ltd Financial Statement

Krebs Biochemicals & Industries Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue6.44
Operating Expense11.51
Net Profit-8.27
Net Profit Margin-128.42
Earning Per Share-3.83
EBIDTA-5.07
Effective Tax Rate-0.39

Krebs Biochemicals & Industries Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual50.42
Operating Expenses Annual59.15
Operating Profit Annual-8.27
Interest Annual4.69
Depreciation6.77
Net Profit Annual-19.73
Tax AnnualTBA

Krebs Biochemicals & Industries Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.09
Cash Flow from Operations2.30
Cash Flow from Investing-7.82
Cash Flow from Financing5.56
Cash Flow at the End0.14

Krebs Biochemicals & Industries Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)-16.40
PBIT Margin (%)-29.83
PBT Margin (%)-23.46
Net PROFIT Margin (%)-39.13
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-14.87
Total Debt / Equity (X)2.83
Asset Turnover Ratio (%)0.38

Krebs Biochemicals & Industries Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual151.80
Total Current Assets Annual17.44
Non Current Assets Annual160.73
Total Shareholders Funds Annual-119.22
Total Assets Annual178.17

Krebs Biochemicals & Industries Ltd Earning Calls

No Data Availabe

FAQS on Krebs Biochemicals & Industries Ltd Financials

As of Jun 3, 2025, Krebs Biochemicals & Industries Ltd has a market capitalization of 144 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Krebs Biochemicals & Industries Ltd is with a debt-to-equity ratio of -1.45.

In FY 2024 , Krebs Biochemicals & Industries Ltd recorded a total revenue of approximately 43.31 Cr marking a significant milestone in the company's financial performance.

Krebs Biochemicals & Industries Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and -0.1% annually, respectively..

Krebs Biochemicals & Industries Ltd's current PE ratio is -5.35.

Krebs Biochemicals & Industries Ltd's ROCE averaged -15.6% from the FY ending March 2023 to 2025, with a median of -16.0%. It peaked at -12.2% in March 2024, reflecting strong capital efficiency over the period..

Krebs Biochemicals & Industries Ltd's latest EBIT is Rs. -21.01 Cr, surpassing the average EBIT of Rs. -19.26 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions